Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 685509 alone or with empagliflozin in compensated cirrhosis with clinically significant portal hypertension
NL-OMON58649Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of avenciguat and empagliflozin in Portal Hypertension (PH), Cirrhosis, metabolic dysfunction-associated steatohepatitis (MASH) and 2 more (2 arms), sponsored by Boehringer Ingelheim. Started Sep 2022; status: completed.
02
Drugs
avenciguatempagliflozin
03
Conditions
Portal Hypertension (PH)Cirrhosismetabolic dysfunction-associated steatohepatitis (MASH)hepatitis B (HBV)hepatitis C virus infection
Beyond the preview
Go deeper on NL-OMON58649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58649.